A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity

Krishna Das, Elodie Belnoue, Matteo Rossi, Tamara Hofer, Sarah Danklmaier, Tobias Nolden, Liesa-Marie Schreiber, Katharina Angerer, Janine Kimpel, Sandra Hoegler, Bart Spiesschaert, Lukas Kenner, Dorothee Laer, Knut Elbers, Madiha Derouazi () and Guido Wollmann ()
Additional contact information
Krishna Das: Medical University of Innsbruck
Elodie Belnoue: AMAL Therapeutics
Matteo Rossi: AMAL Therapeutics
Tamara Hofer: Medical University of Innsbruck
Sarah Danklmaier: Medical University of Innsbruck
Tobias Nolden: Boehringer Ingelheim International GmbH
Liesa-Marie Schreiber: Medical University of Innsbruck
Katharina Angerer: Medical University of Innsbruck
Janine Kimpel: Institute of Virology, Medical University of Innsbruck
Sandra Hoegler: University of Veterinary Medicine Vienna
Bart Spiesschaert: Boehringer Ingelheim International GmbH
Lukas Kenner: University of Veterinary Medicine Vienna
Dorothee Laer: Institute of Virology, Medical University of Innsbruck
Knut Elbers: Boehringer Ingelheim International GmbH
Madiha Derouazi: AMAL Therapeutics
Guido Wollmann: Medical University of Innsbruck

Nature Communications, 2021, vol. 12, issue 1, 1-14

Abstract: Abstract Functional tumor-specific cytotoxic T cells elicited by therapeutic cancer vaccination in combination with oncolytic viruses offer opportunities to address resistance to checkpoint blockade therapy. Two cancer vaccines, the self-adjuvanting protein vaccine KISIMA, and the recombinant oncolytic vesicular stomatitis virus pseudotyped with LCMV-GP expressing tumor-associated antigens, termed VSV-GP-TAA, both show promise as a single agent. Here we find that, when given in a heterologous prime-boost regimen with an optimized schedule and route of administration, combining KISIMA and VSV-GP-TAA vaccinations induces better cancer immunity than individually. Using several mouse tumor models with varying degrees of susceptibility for viral replication, we find that priming with KISIMA-TAA followed by VSV-GP-TAA boost causes profound changes in the tumor microenvironment, and induces a large pool of poly-functional and persistent antigen-specific cytotoxic T cells in the periphery. Combining this heterologous vaccination with checkpoint blockade further improves therapeutic efficacy with long-term survival in the spectrum. Overall, heterologous vaccination with KISIMA and VSV-GP-TAA could sensitize non-inflamed tumors to checkpoint blockade therapy.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25506-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25506-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25506-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().